Patients with a personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN2) should not use this medication
In general, and similar to FDA-approved labeling for GLP-1 weight-management medications, you may be considered for a GLP-1 prescription if you: Have a BMI of 30 or higher (obesity), or Have a BMI between 2729.9 (overweight) plus a weight-related health condition Weight-related conditions can include high blood pressure, type 2 diabetes, sleep apnea, high cholesterol, or PCOS (Polycystic Ovary Syndrome), for example
Glutathione deficiency is associated with age-related diseases, including Alzheimer's disease, cancer, liver disease, diabetes, and others
No peptide is FDA-approved specifically for injury recovery as of 2026
The paradox, resolved: glucagon was never the villain
A vial can have 99.5% purity and still contain dramatically less tirzepatide than the label claims